Demystifying Functional Parameters for Irreversible Enzyme Inhibitors.
作者信息
Heppner David E, Ogboo Blessing C, Urul Daniel A, May Earl W, Schaefer Erik M, Murkin Andrew S, Gehringer Matthias
机构信息
Department of Chemistry, The State University of New York at Buffalo. Buffalo, New York 14221, United States.
AssayQuant Technologies Inc., Marlboro, Massachusetts 01752, United States.
出版信息
J Med Chem. 2024 Sep 12;67(17):14693-14696. doi: 10.1021/acs.jmedchem.4c01721. Epub 2024 Aug 8.
Abstract
摘要
相似文献
1
Demystifying Functional Parameters for Irreversible Enzyme Inhibitors.揭开不可逆酶抑制剂功能参数的神秘面纱。
J Med Chem. 2024 Sep 12;67(17):14693-14696. doi: 10.1021/acs.jmedchem.4c01721. Epub 2024 Aug 8.
2
Mathematica program: its use to simulate metabolic irreversible pathways and inhibition of the first enzyme of a pathway by its end product as visualized with the reservoir model.Mathematica 程序：使用该程序通过储库模型模拟代谢不可逆途径和途径中第一个酶被其终产物抑制的情况。
Comput Biol Med. 2013 Aug 1;43(7):853-64. doi: 10.1016/j.compbiomed.2013.04.003. Epub 2013 Apr 18.
3
Metalloenzymes as Therapeutic Targets.金属酶作为治疗靶点
Curr Med Chem. 2019;26(15):2556-2557. doi: 10.2174/092986732615190725122012.
4
Generalized theoretical and practical treatment of the kinetics of an enzyme-catalyzed reaction in the presence of an enzyme equimolar irreversible inhibitor.在存在等摩尔不可逆酶抑制剂的情况下，酶催化反应动力学的广义理论与实践处理
J Chem Inf Comput Sci. 2003 Sep-Oct;43(5):1486-93. doi: 10.1021/ci0304021.
5
Reversible inhibition of enzymatic systems involving covalent intermediates.涉及共价中间体的酶系统的可逆抑制作用。
J Enzyme Inhib. 1997 Feb;11(4):245-64. doi: 10.3109/14756369709027654.
6
Special Issue: "Enzymes and Enzyme Inhibitors-Applications in Medicine and Diagnosis 2.0".特刊：“酶与酶抑制剂——在医学与诊断中的应用2.0”
Int J Mol Sci. 2024 Dec 14;25(24):13422. doi: 10.3390/ijms252413422.
7
Transition state and multisubstrate analog inhibitors.过渡态和多底物类似物抑制剂
Methods Enzymol. 1995;249:284-312. doi: 10.1016/0076-6879(95)49039-6.
8
Structure-based approaches in modern drug discovery research.现代药物发现研究中基于结构的方法。
Ernst Schering Res Found Workshop. 2001(34):123-42. doi: 10.1007/978-3-662-04645-6_7.
9
Numerical Methods for Modeling Enzyme Kinetics.酶动力学建模的数值方法。
Methods Mol Biol. 2021;2342:147-168. doi: 10.1007/978-1-0716-1554-6_6.
10
Prediction of binding sites in receptor-ligand complexes with the Gaussian Network Model.利用高斯网络模型预测受体-配体复合物中的结合位点。
Phys Rev Lett. 2008 Jun 6;100(22):228102. doi: 10.1103/PhysRevLett.100.228102. Epub 2008 Jun 3.
引用本文的文献
1
Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies.通过表皮生长因子受体（EGFR）导向研究对靶向共价抑制剂进行分析和优化
J Med Chem. 2025 Aug 28;68(16):17917-17932. doi: 10.1021/acs.jmedchem.5c01661. Epub 2025 Aug 13.
2
Design, Synthesis, and Molecular Evaluation of SAr-Reactive N-(6-Fluoro-3-Nitropyridin-2-yl)Isoquinolin-3-Amines as Covalent USP7 Inhibitors Reveals an Unconventional Binding Mode.作为共价USP7抑制剂的SAr反应性N-(6-氟-3-硝基吡啶-2-基)异喹啉-3-胺的设计、合成及分子评价揭示了一种非常规的结合模式。
Arch Pharm (Weinheim). 2025 Aug;358(8):e70053. doi: 10.1002/ardp.70053.
3
Application and Cross-Validation of a High-Throughput SPR Method for Characterizing Covalent Binding Ligands.用于表征共价结合配体的高通量表面等离子体共振方法的应用与交叉验证
ACS Omega. 2025 Jul 4;10(27):29637-29646. doi: 10.1021/acsomega.5c03239. eCollection 2025 Jul 15.
4
Go for Gold: Development of a Scalable Synthesis of [1-(Ethoxycarbonyl)cyclopropyl] Triphenylphosphonium Tetrafluoroborate, a Key Reagent to Explore Covalent Monopolar Spindle 1 Inhibitors.追求卓越：[1-(乙氧羰基)环丙基]三苯基鏻四氟硼酸盐的可扩展合成方法的开发，该盐是探索共价单极纺锤体1抑制剂的关键试剂。
ChemistryOpen. 2025 Sep;14(9):e202500106. doi: 10.1002/open.202500106. Epub 2025 Apr 16.
5
Discovery of a Series of Covalent Ligands That Bind to Cys77 of the Von Hippel-Lindau Tumor Suppressor Protein (VHL).发现一系列与冯·希佩尔-林道肿瘤抑制蛋白（VHL）的半胱氨酸77结合的共价配体。
ACS Med Chem Lett. 2025 Mar 19;16(4):693-699. doi: 10.1021/acsmedchemlett.4c00582. eCollection 2025 Apr 10.
6
Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?共价变构抑制剂：我们能否两全其美？
J Med Chem. 2025 Feb 27;68(4):4040-4052. doi: 10.1021/acs.jmedchem.4c02760. Epub 2025 Feb 12.
7
Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.构象灵活性是设计广谱人诺如病毒蛋白酶抑制剂的关键因素。
J Virol. 2025 Feb 25;99(2):e0175724. doi: 10.1128/jvi.01757-24. Epub 2025 Jan 28.
8
Lazertinib: breaking the mold of third-generation EGFR inhibitors.拉泽替尼：打破第三代表皮生长因子受体抑制剂的常规模式。
RSC Med Chem. 2025 Jan 7;16(3):1049-1066. doi: 10.1039/d4md00800f. eCollection 2025 Mar 19.
9
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase Inhibitors.向表皮生长因子受体（EGFR）突变选择性倾斜天平：扩展二价“V型”激酶抑制剂的范围
J Med Chem. 2024 Dec 12;67(23):21438-21469. doi: 10.1021/acs.jmedchem.4c02311. Epub 2024 Dec 3.
10
A practical guide for the assay-dependent characterisation of irreversible inhibitors.不可逆抑制剂检测依赖性表征实用指南。
RSC Med Chem. 2024 Nov 1. doi: 10.1039/d4md00707g.
本文引用的文献
1
Fitting of and Values from Endpoint Pre-incubation IC Data.根据终点预孵育IC数据拟合 和 值。
ACS Med Chem Lett. 2024 Apr 4;15(5):731-738. doi: 10.1021/acsmedchemlett.4c00054. eCollection 2024 May 9.
2
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.新兴与重现的靶向共价抑制剂弹头：更新。
J Med Chem. 2024 May 23;67(10):7668-7758. doi: 10.1021/acs.jmedchem.3c01825. Epub 2024 May 6.
3
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SAr Electrophiles.基于 SAr 亲电试剂的高效和选择性 FGFR4 共价抑制剂的开发。
J Med Chem. 2024 Apr 25;67(8):6549-6569. doi: 10.1021/acs.jmedchem.3c02483. Epub 2024 Apr 11.
4
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors.将ATP与变构位点相连以实现与二价表皮生长因子受体激酶抑制剂的超加成结合。
Commun Chem. 2024 Feb 20;7(1):38. doi: 10.1038/s42004-024-01108-3.
5
Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors.在确定共价表皮生长因子受体抑制剂的效力和突变选择性时的陷阱和注意事项。
J Med Chem. 2024 Jan 11;67(1):2-16. doi: 10.1021/acs.jmedchem.3c01502. Epub 2023 Dec 22.
6
Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor.低效能靶标抑制可驱动临床 p38 抑制剂的抗癌活性。
Cell Chem Biol. 2023 Oct 19;30(10):1211-1222.e5. doi: 10.1016/j.chembiol.2023.09.013. Epub 2023 Oct 11.
7
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448).来泽替尼（YH25448）抑制突变型表皮生长因子受体的结构基础
ACS Med Chem Lett. 2022 Nov 10;13(12):1856-1863. doi: 10.1021/acsmedchemlett.2c00213. eCollection 2022 Dec 8.
8
Advances in covalent drug discovery.共价药物发现的进展。
Nat Rev Drug Discov. 2022 Dec;21(12):881-898. doi: 10.1038/s41573-022-00542-z. Epub 2022 Aug 25.
9
A Comprehensive Guide for Assessing Covalent Inhibition in Enzymatic Assays Illustrated with Kinetic Simulations.评估酶促分析中共价抑制的综合指南——结合动力学模拟加以说明。
Curr Protoc. 2022 Jun;2(6):e419. doi: 10.1002/cpz1.419.
10
The Ascension of Targeted Covalent Inhibitors.靶向共价抑制剂的崛起。
J Med Chem. 2022 Apr 28;65(8):5886-5901. doi: 10.1021/acs.jmedchem.1c02134. Epub 2022 Apr 19.
Zotero 插件